Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Pimavanserin in Alzheimer's Disease Agitation.

Next Previous
Trial Profile

Phase II Study of Pimavanserin in Alzheimer's Disease Agitation.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pimavanserin (Primary)
  • Indications Agitation
  • Focus Therapeutic Use
  • Acronyms SERENE
  • Sponsors Acadia Pharmaceuticals

    • Most Recent Events

    • 04 Oct 2017 According to a company media release, ACADIA announced that due to the potential overlap of clinical sites and study participants between its Phase III HARMONY dementia-related psychosis study and this trial of pimavanserin in Alzheimer's disease agitation, it has decided to discontinue enrollment of new patients in the SERENE study. Patients already enrolled will complete the study as planned.
    • 04 Oct 2017 Status changed from recruiting to discontinued, according to an Acadia Pharmaceuticals media release.
    • 12 Nov 2016 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top